MiR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 3, 2014, Pages 387-397

  Lu, Ruijing ^a,b   Ji, Ziliang ^a,b   Li, Xiaoqing ^a,b   Zhai, Qingna ^a,b   Zhao, Chunjuan ^a,b   Jiang, Zhimao ^a   Zhang, Shiqiang ^a   Nie, Liping ^a   Yu, Zhendong ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

ANGPT2; miR 145; NEDD9; Renal cell carcinoma; Tumor suppressor

Indexed keywords

ANGIOPOIETIN 2; MICRORNA 145; NEURAL PRECURSOR CELL EXPRESSED DEVELOPMENTALLY DOWNREGULATED PROTEIN 9; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANGIOPOIETIN-2; ANTICARCINOGENIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ONCOGENES; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84896714775     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1577-z     Document Type: Article

References (31)

1. Baldewijns M, Thijssen V, Van den Eynden G, Van Laere S, Bluekens A, Roskams T, Van Poppel H, De Bruine A, Griffioen A, Vermeulen P (2007) High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 96(12):1888-1895
2. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E (2005) Phylogenetic shadowing and computational identification of human micro RNA genes. Cell 120(1):21-24
3. Bullock A, Zhang L, O'Neill A, Percy A, Sukhatme V, Mier J, Atkins M, Bhatt R (2010) Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). J Clin Oncol 2010(28):4630
4. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P (2010) Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10(12):858-870
5. Chang J-X, Gao F, Zhao G-Q, Zhang G-J (2012) Expression and clinical significance of NEDD9 in lung tissues. Med Oncol 29(4):2654-2660
6. Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, Liang S (2012) Roles of microRNA on cancer cell metabolism. J Transl Med 10:228. doi: 10.1186/1479-5876-10-228
7. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M (2010) miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102(5):883-891
8. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. New Engl J Med 353(23):2477-2490
9. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M (2001) Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma possible in vivo regulation via induction of proteases. Cancer Res 61(5):2145-2153
10. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655-664
11. Ha T-Y (2011) MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw 11(3):135-154
12. Honda H, Oda H, Nakamoto T, Honda Z-I, Sakai R, Suzuki T, Saito T, Nakamura K, Nakao K, Ishikawa T (1998) Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet 19(4):361-365
13. Hu B, Cheng S-Y (2009) Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 11(2):111-116
14. Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Bio 11(4):252-263
15. Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A (2009) NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 69(18):7198-7206
16. Kim M, Gans JD, Nogueira C, Wang A, Paik J-H, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125(7):1269-1281
17. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294(5543):853-858
18. Liang C-C, Park AY, Guan J-L (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329-333
19. Natarajan M, Stewart J, Golemis EA, Pugacheva E, Alexandropoulos K, Cox BD, Wang W, Grammer J, Gladson C (2005) HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 25(12):1721-1732
20. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E (2013) Angiogenic axis angiopoietin-1 and angiopoietin-2/tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Neurobiol Respir Spring 341-348
21. Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim S-J, Kwon SH (2013) miR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 335(2):455-462
22. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507-516
23. Pascual D, Borque A (2008) Epidemiology of kidney cancer. Adv Urol 2008:782381
24. Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O (2012) MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumor Biol 34(1):481-491. doi: 10.1007/s13277-012-0573-2
25. Reeves DJ, Liu CY (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemoth Pharm 64(1):11-25
26. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119-1132
27. Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M, Pellegatta S, Finocchiaro G (2012) NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 3(7):723
28. Thurston G, Daly C (2012) The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med 2(9):a006550
29. Zaman M, Chen Y, Deng G, Shahryari V, Suh S, Saini S, Majid S, Liu J, Khatri G, Tanaka Y (2010) The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103(2):256-264
30. Zhao L, Chen X, Cao Y (2011) New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin 43(11):831-839
31. Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, Zhao X, Liang C, Wang Y, Sun L (2010) Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27. 3 associate with clear cell renal cell carcinoma. PLoS ONE 5(12):e15224